Radiological efficacy
SECONDARY
Antitumor efficacy is one of the secondary outcomes of the clinical trial. Confirmed partial responses were observed in 2 out of 11 patients from cohort A1 (18%), 2 out of 6 patients from cohort A2 (33%), and 5 out of 12 patients from cohort B1 (42%, Supplementary Fig. 